Form 4 for LAB STANDARD BIOTOOLS INC.

Accepted 2024-06-21 00:00:00 ET · period of report 2024-06-18 · accession 0000919574-24-003795 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2024-06-21	2024-06-18	LAB	Casdin Capital, LLC	Dir, 10%	J - Other	$2.05	0	545.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-06-18	J	A	655,000	$2.05	46,730,821	I See footnote.	—	—	(F2) The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
2	Common	Common Stock	2024-06-18	J	D	1,200,000	$2.05	0	I See footnote.	—	—	(F6) The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
3	Common	Common Stock	2024-06-18	J	A	545,000	$2.05	545,000	I See footnote.	—	—	(F4) The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.